Pharmaceutical Market Europe • March 2021 • 3
COMMENT
Rare Disease Day 2021 fell on 28 February this year and aims to raise awareness among the general public and decision-makers about rare diseases and the impact these conditions have on patients’ lives.
According to Rare Disease UK, one in 17 people will be affected by a rare disease at some point during their lifetime, with 3.5 million people in the UK and 30 million people across Europe living with a rare disease.
In 2021, Rare Disease Day focused on the global rare diseases community by spotlighting six continents, six portraits, six heroes, six lives, featuring individuals living with a different rare disease and facing similar challenges.
Also marking Rare Disease Day 2021, biotech company bluebird bio highlighted the personal stories of nine patients from seven countries, aged between four and 61, living with the rare inherited blood disorder thalassaemia.
The nine patients are featured in a video – ‘Living with Thalassaemia in Europe: Stories from patients of different ages’ – along with national patient group representatives and quotes from clinicians.
The video, filmed during the COVID-19 pandemic, tells the patients’ stories through a mix of selfie videos, still photography and animated facts to show the day-to-day perspectives of living with this condition. Read more about Rare Disease Day on page 25.
In Chris Ross’ article on page 28, Chris looks at mapping the patient journey, focusing on eight ways to improve support programmes. He examines how pharma can drive awareness and adoption of patient support solutions and emphasises that the job of a patient support programme isn’t to make patients reliant on that programme, but to give them the skills, confidence and knowledge to be independent without it.
I hope you enjoy this issue!
Iona Everson
Group Managing Editor
Keep up to date with the latest developments in the UK and global healthcare marketplace – sign up to daily or weekly news alerts and fortnightly or monthly bulletins on specific topics at www.pmlive.com/register
THE TEAM
Editorial:
Group Managing Editor
Iona Everson
Reporter
Lucy Parsons
Studio:
Executive Director
Karl Equi
Middleweight Graphic Designer
Helen Penfold
Sales:
Business Director
Tara Lovegrove
EDITORIAL ADVISORY BOARD
Philip Atkinson
Founder of Hive-Logic, Lifescience Transformation
Uday Bose
Corporate vice president, head of global marketing oncology, Boehringer Ingelheim
Dr Luc Hermans
VP commercial planning and operations Europe, Asia, Middle East, Gilead Sciences
Stefan Janssens
President EMEA, Cegedim Dendrite
John Morris
Partner, KPMG
Paul Pay
Chief business development officer, Norgine
Mark Rothera
Chief executive officer, Orchard Therapeutics
Ian Talmage
Senior vice president, global marketing, general medicine, Bayer Pharmaceuticals
PUBLISHED BY
PMGroup
Mansard House, Church Road, Little Bookham, Surrey, KT23 3JG, UK
Tel: +44 (0)1372 414200
Fax: +44 (0)1372 414201
CONTACT US
General enquiries: info@pmlive.com
Editorial: editor@pmlive.com
Advertising: sales@pmlive.com
Subscriptions: subscriptions@pmlive.com
Views expressed by the contributors do not necessarily represent those of the publisher, editor or staff.
© 2021 PMGroup
All rights reserved. No part of this publication may be copied, reproduced, transmitted, photocopied, recorded or stored on any retrieval system without the prior written consent of the publishers.
The magazine is also available at the following subscription rates: £120 UK, £180 Europe, £210 RoW